NCT00875004 2024-06-26
PLATON
Institut du Cancer de Montpellier - Val d'Aurelle
Phase NA Terminated
Clinical Trials
13 trialsNCT02761642 2018-08-24
A Study to Evaluate Efficacy and Safety of Epoetin Beta (NeoRecormon®) in Anemic Participants With Breast Cancer Undergoing Chemotherapy
Hoffmann-La Roche
Phase 2 Completed
NCT00776425 2017-07-02
A Study of the Quality of Life and Treatment Response to Once Weekly Epoetin Beta (Recormon) Treatment in Anemic Participants With Solid and Lymphoid Malignancies
Hoffmann-La Roche
Phase 4 Completed
NCT02767765 2017-04-04
A Study of Recombinant Human Erythropoietin Beta (NeoRecormon) in Anemic Cancer Participants Treated With Chemotherapy
Hoffmann-La Roche
Phase 3 Completed
NCT02554942 2016-11-02
A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors
Hoffmann-La Roche
Phase 4 Completed
NCT02564094 2016-11-02
A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors or Hematologic Malignancies
Hoffmann-La Roche
Phase 4 Completed
NCT02608060 2016-11-02
A Study to Assess the Hematopoyetic Response of Anemic Patients With Hematologic Malignancies Treated With Erythropoietin B
Hoffmann-La Roche
Phase 4 Terminated
NCT02624141 2016-11-02
A Study of Recormon (Epoetin Beta) in Anemic Patients With Non-Myeloid Malignancy
Hoffmann-La Roche
Phase 4 Terminated
NCT01809314 2016-08-19
An Observational Study of Epoetin Beta (NeoRecormon) in Participants With Cancer Receiving Chemotherapy
Hoffmann-La Roche
Completed
NCT01168349 2015-10-02
An Observational Study of NeoRecormon (Epoetin Beta) in Cancer Patients With Anemia (FAST)
Hoffmann-La Roche
Completed
NCT00482716 2014-01-10
Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00046969 2013-05-30
Epoetin Beta in Treating Anemia in Patients With Cervical Cancer
National Cancer Institute (NCI)
Phase 4 Completed
NCT00559195 2011-05-16
Epoetin Beta in Treating Fatigue and Anemia in Patients Receiving Palliative Care for Malignant Solid Tumors
National Cancer Institute (NCI)
Phase 2 Completed